Skip to content

Patient guide • SI Medical Weight Loss

Understanding
Retatrutide

Clear information for your next conversation.

Curious about retatrutide for weight loss? Learn what is being studied, what remains uncertain, and which questions to bring to your healthcare provider.

Discuss Your Weight Loss Options

Explore Our Medical Weight Loss Program

Current status

Investigational medicine.
Research in progress.

Not FDA approved. Retatrutide remains under investigation.*

Read the FDA’s current information

A local place to talk through your weight-management questions.

Start with the basics

What is retatrutide?

Retatrutide is an investigational medicine being developed by Lilly. It targets three hormone receptors: GIP, GLP-1, and glucagon. Researchers are studying its effects on weight and metabolic health.

* “Triple agonist” refers to three receptor targets, not three times the benefit. Retatrutide is investigational and is not approved for routine treatment. Study findings are not personal treatment recommendations or guaranteed outcomes.

Read Lilly’s retatrutide overview

Put the headlines in context

Research is a starting point.
Your care is personal.

Explore who took part in the research, what was measured, and how safety was monitored.*

01

What has been studied?

Trials have examined retatrutide in adults with obesity or overweight. The TRIUMPH-1 study record describes the study design, eligibility criteria, and outcomes.

02

What about side effects?

In the published Phase 2 trial, gastrointestinal side effects were the most common adverse events. Investigators also observed increases in heart rate.*

03

What remains uncertain?

* Research and regulatory review are ongoing. These findings are not a complete safety profile and do not establish an approved dose or an individual treatment recommendation.

Read the published Phase 2 study

View the TRIUMPH-1 trial record

Availability & safety

Understand access.
Bring your questions.

Ask your healthcare provider about the research, the exact medicine being discussed, and the weight-management options appropriate for your care.*

Review the FDA’s guidance

* The FDA warns against retatrutide sold to consumers for “research purposes” or “not for human consumption”: quality is unknown and it may be harmful. FDA also states that retatrutide cannot be used in compounding under federal law. An online price or vial label does not establish approval or legitimate access.

Questions worth asking

What is the exact product and its current approval status?

What evidence applies to my medical history?

What are the risks, alternatives, and follow-up needs?

If a clinical trial interests me, who can explain its eligibility and consent process?

Your next step at SI Medical

A plan built around you.

You do not need to choose a medication before your first conversation. At our family-owned clinics in Marion and Belleville, a medical weight loss appointment starts with your history, your goals, and your questions.

Our program includes consultation and examination, body composition assessment, nutrition and activity guidance, monthly follow-ups, and transition and maintenance support. Your provider can discuss treatment options appropriate for your individual needs.

Explore Our Medical Weight Loss Program

Learn About Semaglutide

Make your visit useful

Bring your medication and supplement list, relevant health history, and notes about previous weight loss efforts. Share what matters most to you, including tolerability, follow-up support, and cost.

For current program pricing, visit our pricing page. Confirm the exact recommended treatment and what your plan includes with the clinic.

Schedule a Weight Loss Appointment

Your questions, answered

Clarity before
the next step.

Use this guide to prepare for a conversation with a healthcare professional. Your own medical history deserves individual attention.

Is retatrutide the same as semaglutide or tirzepatide?

No. These are different medicines. Retatrutide is being investigated as a triple-receptor agonist and should not be treated as interchangeable with another prescription.

Is “GLP-3” another name for retatrutide?

You may see that nickname online. Lilly explains that it is not a scientific classification. “Triple agonist” describes retatrutide’s receptor targets more accurately.

Can I use this page as dosing guidance?

No. Study protocols are research documents, not instructions for self-treatment. This guide does not provide a dosing schedule or instructions for obtaining retatrutide.

Does this page mean SI Medical offers retatrutide?

This is an educational resource, not confirmation of availability or a prescription offer. Contact the clinic to discuss your current care options and the exact treatment being recommended.

Can I discuss weight loss options now?

Yes. Call SI Medical to arrange a medical weight loss appointment in Marion or Belleville and discuss your goals and next steps.*

Care close to home

Talk with a local team.

Choose the clinic that works for you and call to schedule a medical weight loss appointment.

Marion, IL

1909 Coolidge Ave.
Marion, IL 62959

Call Marion: 618-997-5677
SI Medical Weight Loss Belleville Office

Belleville, IL

123 Lincoln Place Court
Belleville, IL 62221

Call Belleville: 618-234-5677

Keep the information in context

Sources & further reading

* This is an educational research guide, not confirmation that SI Medical offers retatrutide, an instruction for self-treatment, or a promise of a prescription. Research and regulatory status can change. Individual medical advice and treatment decisions require your healthcare provider.

FDA: Retatrutide and unapproved weight loss products

Lilly: What to know about retatrutide

ClinicalTrials.gov: TRIUMPH-1 (NCT05929066)

Published Phase 2 study: abstract and citation

Start with a conversation

Your questions belong
in your care plan.

Talk with SI Medical about your goals and the weight-management options that may fit your needs.

Discuss Your Weight Loss Options

Medical evaluation required. Treatment recommendations are individual.